This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsSilo Wellness（SILF.F）株式概要A psychedelics and wellness company, develops psychedelic medicine to reduce trauma. 詳細SILF.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績2/6財務の健全性0/6配当金0/6報酬株価収益率（ 2.2 x） US市場（ 18.6 x）を下回っています。今年は黒字化を達成 リスク分析意味のある時価総額がありません ( $1M )収益が 100 万ドル未満 ( $276K )マイナスの株主資本 過去1年間で株主の希薄化は大幅に進んだ +3 さらなるリスクすべてのリスクチェックを見るSILF.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.011202.7% 割高 内在価値ディスカウントEst. Revenue$PastFuture-5m511k2016201920222025202620282031Revenue US$275.9kEarnings US$511.0kAdvancedSet Fair ValueView all narrativesSilo Wellness Inc. 競合他社Evofem BiosciencesSymbol: OTCPK:EVFMMarket cap: US$866.7kSeelos TherapeuticsSymbol: OTCPK:SEEL.QMarket cap: US$136.0Kaya HoldingsSymbol: OTCPK:KAYSMarket cap: US$23.3mWEEDSymbol: OTCPK:BUDZMarket cap: US$4.6m価格と性能株価の高値、安値、推移の概要Silo Wellness過去の株価現在の株価CA$0.01152週高値CA$0.02952週安値CA$0.0037ベータ0.661ヶ月の変化0%3ヶ月変化53.42%1年変化26.41%3年間の変化n/a5年間の変化n/aIPOからの変化-99.63%最新ニュースお知らせ • Aug 30+ 1 more updateSilo Wellness Inc. announced that it expects to receive CAD 0.25 million in fundingSilo Wellness Inc. announced a best-efforts private placement to issue 12,500,000 common shares at a price of CAD 0.02 per share for the gross proceeds of CAD 250,000 on August 29, 2023.お知らせ • Feb 18Silo Wellness Inc. Announces Resignation of Gerard Lee from as A Director of the BoardSilo Wellness Inc. accepted the resignation of Gerard Lee from his position as a director of the board, effective immediately. The board of directors includes Greg Biniowsky (independent director), Vancouver lawyer; Simon Bababeygy, M.D. (independent director), California physician; Michael Hartman, California pharmaceutical chemist; and Mike Arnold, Oregon lawyer.お知らせ • Oct 18Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Silo Wellness Inc. (CNSX:SILO) entered into a definitive share exchange agreement to acquire Dyscovry Science Ltd. on September 27, 2022. Pursuant to the terms of the Share Exchange Agreement, Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange for 12,762,325 (for a total of 49% of the issued shares post closing of the transaction) common shares in the capital of Silo (the "Payment Shares"). The Payment Shares issued for shares of Dyscovry shall be subject to restrictions on resale for a period of 36 months from closing of the Acquisition and shall be released on a schedule consistent with the release schedule for an "emerging issuer" prescribed by section 4.3 of National Policy 46-201- Escrow for Initial Public Offerings. Silo has also agreed to pay approximately CAD 120,000 of Dyscovry founder's debt in twelve equal monthly installments, and in any event, the total debt shall be paid no later than twelve months from the Closing Date. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange of 49% of the issued shares. Following closing, Dyscovry shall have the right to immediately nominate one director to the board of directors of Silo. Closing of the Transaction is subject to customary closing conditions and applicable regulatory approvals, including the approval of the CSE and the shareholders of Dyscovry if required. Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd. on October 17, 2022. Upon closing of the transaction, CFO Winfield Ding has resigned from the board of directors and Dyscovry founder Gerard Lee of Toronto has been appointed director. Winfield Ding will continue as Chief Financial Officer.お知らせ • Jun 10Silo Wellness Inc. Announces Change of Chief Executive OfficerSilo Wellness Inc. announced that founder and chairman of the board of directors Mike Arnold is assuming the role of the company's interim chief executive officer to continue to lead the company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. CEO Mike Arnold founded Silo Wellness in 2018 and was CEO from inception until August 2020. He is an experienced Oregon trial attorney. As the company's president and chairman of the board of directors, he has been responsible for the Company's Ontario Securities Commission and Canadian Securities Exchange compliance, investor relations, financing, and corporate development. In the last five years he has successfully raised over $12 million for his startups. Mike received his Bachelor of Arts from Truman State University (Kirksville, Missouri) and Juris Doctor from the University of Oregon School of Law. He is an avid outdoorsman and rafting guide.お知らせ • Jun 01Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo Wellness Inc. acquiring 100% of Dyscovry's shares in exchange for 49% of the issued outstanding securities of the Company.お知らせ • Apr 15Silo Wellness Inc. announced that it expects to receive CAD 5.95 million in funding from Alpha Blue Ocean Investment GroupSilo Wellness Inc. announced that it has entered into an subscription agreement for a private placement of convertible debentures for gross proceeds of up to CAD 5,950,000 on April 14, 2022. The transaction will include participation from new investor Global Tech Opportunities 14, a fund managed by Alpha Blue Ocean Investment Group. The subscription agreement provides a commitment to fund the corporation up to CAD 5,950,000 by subscribing for CAD 7,300,000 aggregate principal amount of convertible debentures, inclusive of the commitment fee, in twenty tranches, each in the aggregate principal amount of CAD 350,000 each tranche convertible upon notice at the lower of the closing price of the common shares on the CSE at the time of delivery of the relevant conversion notice to the corporation and CAD 0.05; the convertible debentures shall be subscribed for at a subscription price of eighty-five percent of the par value of the convertible debentures. 41,650,000 warrants exercisable at CAD 0.05 shall be attached to the first tranche. In connection with the subscription agreement, the company has agreed to pay the subscriber a commitment fee of CAD 300,000 where CAD 150,000 shall be added to the principal amount of the debentures issued in connection with each of the first two tranches.最新情報をもっと見るRecent updatesお知らせ • Aug 30+ 1 more updateSilo Wellness Inc. announced that it expects to receive CAD 0.25 million in fundingSilo Wellness Inc. announced a best-efforts private placement to issue 12,500,000 common shares at a price of CAD 0.02 per share for the gross proceeds of CAD 250,000 on August 29, 2023.お知らせ • Feb 18Silo Wellness Inc. Announces Resignation of Gerard Lee from as A Director of the BoardSilo Wellness Inc. accepted the resignation of Gerard Lee from his position as a director of the board, effective immediately. The board of directors includes Greg Biniowsky (independent director), Vancouver lawyer; Simon Bababeygy, M.D. (independent director), California physician; Michael Hartman, California pharmaceutical chemist; and Mike Arnold, Oregon lawyer.お知らせ • Oct 18Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Silo Wellness Inc. (CNSX:SILO) entered into a definitive share exchange agreement to acquire Dyscovry Science Ltd. on September 27, 2022. Pursuant to the terms of the Share Exchange Agreement, Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange for 12,762,325 (for a total of 49% of the issued shares post closing of the transaction) common shares in the capital of Silo (the "Payment Shares"). The Payment Shares issued for shares of Dyscovry shall be subject to restrictions on resale for a period of 36 months from closing of the Acquisition and shall be released on a schedule consistent with the release schedule for an "emerging issuer" prescribed by section 4.3 of National Policy 46-201- Escrow for Initial Public Offerings. Silo has also agreed to pay approximately CAD 120,000 of Dyscovry founder's debt in twelve equal monthly installments, and in any event, the total debt shall be paid no later than twelve months from the Closing Date. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange of 49% of the issued shares. Following closing, Dyscovry shall have the right to immediately nominate one director to the board of directors of Silo. Closing of the Transaction is subject to customary closing conditions and applicable regulatory approvals, including the approval of the CSE and the shareholders of Dyscovry if required. Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd. on October 17, 2022. Upon closing of the transaction, CFO Winfield Ding has resigned from the board of directors and Dyscovry founder Gerard Lee of Toronto has been appointed director. Winfield Ding will continue as Chief Financial Officer.お知らせ • Jun 10Silo Wellness Inc. Announces Change of Chief Executive OfficerSilo Wellness Inc. announced that founder and chairman of the board of directors Mike Arnold is assuming the role of the company's interim chief executive officer to continue to lead the company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. CEO Mike Arnold founded Silo Wellness in 2018 and was CEO from inception until August 2020. He is an experienced Oregon trial attorney. As the company's president and chairman of the board of directors, he has been responsible for the Company's Ontario Securities Commission and Canadian Securities Exchange compliance, investor relations, financing, and corporate development. In the last five years he has successfully raised over $12 million for his startups. Mike received his Bachelor of Arts from Truman State University (Kirksville, Missouri) and Juris Doctor from the University of Oregon School of Law. He is an avid outdoorsman and rafting guide.お知らせ • Jun 01Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo Wellness Inc. acquiring 100% of Dyscovry's shares in exchange for 49% of the issued outstanding securities of the Company.お知らせ • Apr 15Silo Wellness Inc. announced that it expects to receive CAD 5.95 million in funding from Alpha Blue Ocean Investment GroupSilo Wellness Inc. announced that it has entered into an subscription agreement for a private placement of convertible debentures for gross proceeds of up to CAD 5,950,000 on April 14, 2022. The transaction will include participation from new investor Global Tech Opportunities 14, a fund managed by Alpha Blue Ocean Investment Group. The subscription agreement provides a commitment to fund the corporation up to CAD 5,950,000 by subscribing for CAD 7,300,000 aggregate principal amount of convertible debentures, inclusive of the commitment fee, in twenty tranches, each in the aggregate principal amount of CAD 350,000 each tranche convertible upon notice at the lower of the closing price of the common shares on the CSE at the time of delivery of the relevant conversion notice to the corporation and CAD 0.05; the convertible debentures shall be subscribed for at a subscription price of eighty-five percent of the par value of the convertible debentures. 41,650,000 warrants exercisable at CAD 0.05 shall be attached to the first tranche. In connection with the subscription agreement, the company has agreed to pay the subscriber a commitment fee of CAD 300,000 where CAD 150,000 shall be added to the principal amount of the debentures issued in connection with each of the first two tranches.お知らせ • Feb 04Silo Wellness Inc. announced that it expects to receive $0.494988 million in funding from Orthogonal Thinker, Inc., Investment ArmSilo Wellness Inc. announced that it has entered into an subscription agreement to issue 12,555,180 units at a price of $0.039425 per unit for gross proceeds of up to $494,988 on February 3, 2022. The transaction will include participation from new investor Orthogonal Thinker, Inc., Investment Arm. Each unit will consist of one common share and one common share purchase warrant. Each warrant will be exercisable at CAD 0.05 per share for two years following the closing date of the offering. The offering is subject to customary closing conditions, applicable regulatory approvals, including receipt of certain voting support agreements from certain shareholders of the company. David Nikzad and Jason Hobson from Orthogonal Thinker, Inc., Investment Arm will join company's board of director.お知らせ • Jun 25Silo Wellness Inc. Debuts Marley One, the First Global Functional and Psychedelic Mushroom Brand, in Collaboration with the Bob Marley FamilySilo Wellness Inc. announced the launch of Marley One, the first global functional and psychedelic mushroom consumer brand, in collaboration with the family of Bob Marley. The initial product offering will include a range of functional mushroom tinctures with unique blends highlighting the brand’s connection to Jamaica, including species such as cordyceps, lion's mane, chaga, reishi and turkey tail that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. The Company intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics. In March, Silo Wellness announced a multi-year licensing agreement with the family of global reggae icon Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. At launch, the Marley One product line includes: One Mind: A coffee-flavored blend of lion’s mane and L-theanine designed to improve focus and cognitive function. One Flow: A peppermint-flavored blend of cordyceps and ginseng designed to enhance physical endurance and mental function. One Harmony: A mango-flavored blend of chaga and ginger designed to stimulate gut health and improve digestion. One Body: A berry-flavored blend of turkey tail and astragalus designed to support immune health. One Rest: A vanilla-flavored blend of reishi and GABA designed to help reduce tension and stress and improve quality of sleep.株主還元SILF.FUS PharmaceuticalsUS 市場7D0%4.9%1.0%1Y26.4%44.2%28.7%株主還元を見る業界別リターン: SILF.F過去 1 年間で44.2 % の収益を上げたUS Pharmaceuticals業界を上回りました。リターン対市場: SILF.F過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。価格変動Is SILF.F's price volatile compared to industry and market?SILF.F volatilitySILF.F Average Weekly Movementn/aPharmaceuticals Industry Average Movement10.1%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: SILF.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のSILF.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aMike Arnoldwww.silowellness.comもっと見るSilo Wellness Inc. 基礎のまとめSilo Wellness の収益と売上を時価総額と比較するとどうか。SILF.F 基礎統計学時価総額US$1.13m収益（TTM）US$511.02k売上高(TTM)US$275.89k2.2xPER（株価収益率4.1xP/SレシオSILF.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SILF.F 損益計算書（TTM）収益US$275.89k売上原価US$180.23k売上総利益US$95.66kその他の費用-US$415.36k収益US$511.02k直近の収益報告Jul 31, 2023次回決算日該当なし一株当たり利益（EPS）0.0033グロス・マージン34.67%純利益率185.23%有利子負債／自己資本比率-47.5%SILF.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/11/25 18:13終値2023/08/28 00:00収益2023/07/31年間収益2022/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Silo Wellness Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 30+ 1 more updateSilo Wellness Inc. announced that it expects to receive CAD 0.25 million in fundingSilo Wellness Inc. announced a best-efforts private placement to issue 12,500,000 common shares at a price of CAD 0.02 per share for the gross proceeds of CAD 250,000 on August 29, 2023.
お知らせ • Feb 18Silo Wellness Inc. Announces Resignation of Gerard Lee from as A Director of the BoardSilo Wellness Inc. accepted the resignation of Gerard Lee from his position as a director of the board, effective immediately. The board of directors includes Greg Biniowsky (independent director), Vancouver lawyer; Simon Bababeygy, M.D. (independent director), California physician; Michael Hartman, California pharmaceutical chemist; and Mike Arnold, Oregon lawyer.
お知らせ • Oct 18Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Silo Wellness Inc. (CNSX:SILO) entered into a definitive share exchange agreement to acquire Dyscovry Science Ltd. on September 27, 2022. Pursuant to the terms of the Share Exchange Agreement, Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange for 12,762,325 (for a total of 49% of the issued shares post closing of the transaction) common shares in the capital of Silo (the "Payment Shares"). The Payment Shares issued for shares of Dyscovry shall be subject to restrictions on resale for a period of 36 months from closing of the Acquisition and shall be released on a schedule consistent with the release schedule for an "emerging issuer" prescribed by section 4.3 of National Policy 46-201- Escrow for Initial Public Offerings. Silo has also agreed to pay approximately CAD 120,000 of Dyscovry founder's debt in twelve equal monthly installments, and in any event, the total debt shall be paid no later than twelve months from the Closing Date. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange of 49% of the issued shares. Following closing, Dyscovry shall have the right to immediately nominate one director to the board of directors of Silo. Closing of the Transaction is subject to customary closing conditions and applicable regulatory approvals, including the approval of the CSE and the shareholders of Dyscovry if required. Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd. on October 17, 2022. Upon closing of the transaction, CFO Winfield Ding has resigned from the board of directors and Dyscovry founder Gerard Lee of Toronto has been appointed director. Winfield Ding will continue as Chief Financial Officer.
お知らせ • Jun 10Silo Wellness Inc. Announces Change of Chief Executive OfficerSilo Wellness Inc. announced that founder and chairman of the board of directors Mike Arnold is assuming the role of the company's interim chief executive officer to continue to lead the company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. CEO Mike Arnold founded Silo Wellness in 2018 and was CEO from inception until August 2020. He is an experienced Oregon trial attorney. As the company's president and chairman of the board of directors, he has been responsible for the Company's Ontario Securities Commission and Canadian Securities Exchange compliance, investor relations, financing, and corporate development. In the last five years he has successfully raised over $12 million for his startups. Mike received his Bachelor of Arts from Truman State University (Kirksville, Missouri) and Juris Doctor from the University of Oregon School of Law. He is an avid outdoorsman and rafting guide.
お知らせ • Jun 01Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo Wellness Inc. acquiring 100% of Dyscovry's shares in exchange for 49% of the issued outstanding securities of the Company.
お知らせ • Apr 15Silo Wellness Inc. announced that it expects to receive CAD 5.95 million in funding from Alpha Blue Ocean Investment GroupSilo Wellness Inc. announced that it has entered into an subscription agreement for a private placement of convertible debentures for gross proceeds of up to CAD 5,950,000 on April 14, 2022. The transaction will include participation from new investor Global Tech Opportunities 14, a fund managed by Alpha Blue Ocean Investment Group. The subscription agreement provides a commitment to fund the corporation up to CAD 5,950,000 by subscribing for CAD 7,300,000 aggregate principal amount of convertible debentures, inclusive of the commitment fee, in twenty tranches, each in the aggregate principal amount of CAD 350,000 each tranche convertible upon notice at the lower of the closing price of the common shares on the CSE at the time of delivery of the relevant conversion notice to the corporation and CAD 0.05; the convertible debentures shall be subscribed for at a subscription price of eighty-five percent of the par value of the convertible debentures. 41,650,000 warrants exercisable at CAD 0.05 shall be attached to the first tranche. In connection with the subscription agreement, the company has agreed to pay the subscriber a commitment fee of CAD 300,000 where CAD 150,000 shall be added to the principal amount of the debentures issued in connection with each of the first two tranches.
お知らせ • Aug 30+ 1 more updateSilo Wellness Inc. announced that it expects to receive CAD 0.25 million in fundingSilo Wellness Inc. announced a best-efforts private placement to issue 12,500,000 common shares at a price of CAD 0.02 per share for the gross proceeds of CAD 250,000 on August 29, 2023.
お知らせ • Feb 18Silo Wellness Inc. Announces Resignation of Gerard Lee from as A Director of the BoardSilo Wellness Inc. accepted the resignation of Gerard Lee from his position as a director of the board, effective immediately. The board of directors includes Greg Biniowsky (independent director), Vancouver lawyer; Simon Bababeygy, M.D. (independent director), California physician; Michael Hartman, California pharmaceutical chemist; and Mike Arnold, Oregon lawyer.
お知らせ • Oct 18Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Silo Wellness Inc. (CNSX:SILO) entered into a definitive share exchange agreement to acquire Dyscovry Science Ltd. on September 27, 2022. Pursuant to the terms of the Share Exchange Agreement, Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange for 12,762,325 (for a total of 49% of the issued shares post closing of the transaction) common shares in the capital of Silo (the "Payment Shares"). The Payment Shares issued for shares of Dyscovry shall be subject to restrictions on resale for a period of 36 months from closing of the Acquisition and shall be released on a schedule consistent with the release schedule for an "emerging issuer" prescribed by section 4.3 of National Policy 46-201- Escrow for Initial Public Offerings. Silo has also agreed to pay approximately CAD 120,000 of Dyscovry founder's debt in twelve equal monthly installments, and in any event, the total debt shall be paid no later than twelve months from the Closing Date. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange of 49% of the issued shares. Following closing, Dyscovry shall have the right to immediately nominate one director to the board of directors of Silo. Closing of the Transaction is subject to customary closing conditions and applicable regulatory approvals, including the approval of the CSE and the shareholders of Dyscovry if required. Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd. on October 17, 2022. Upon closing of the transaction, CFO Winfield Ding has resigned from the board of directors and Dyscovry founder Gerard Lee of Toronto has been appointed director. Winfield Ding will continue as Chief Financial Officer.
お知らせ • Jun 10Silo Wellness Inc. Announces Change of Chief Executive OfficerSilo Wellness Inc. announced that founder and chairman of the board of directors Mike Arnold is assuming the role of the company's interim chief executive officer to continue to lead the company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. CEO Mike Arnold founded Silo Wellness in 2018 and was CEO from inception until August 2020. He is an experienced Oregon trial attorney. As the company's president and chairman of the board of directors, he has been responsible for the Company's Ontario Securities Commission and Canadian Securities Exchange compliance, investor relations, financing, and corporate development. In the last five years he has successfully raised over $12 million for his startups. Mike received his Bachelor of Arts from Truman State University (Kirksville, Missouri) and Juris Doctor from the University of Oregon School of Law. He is an avid outdoorsman and rafting guide.
お知らせ • Jun 01Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo Wellness Inc. acquiring 100% of Dyscovry's shares in exchange for 49% of the issued outstanding securities of the Company.
お知らせ • Apr 15Silo Wellness Inc. announced that it expects to receive CAD 5.95 million in funding from Alpha Blue Ocean Investment GroupSilo Wellness Inc. announced that it has entered into an subscription agreement for a private placement of convertible debentures for gross proceeds of up to CAD 5,950,000 on April 14, 2022. The transaction will include participation from new investor Global Tech Opportunities 14, a fund managed by Alpha Blue Ocean Investment Group. The subscription agreement provides a commitment to fund the corporation up to CAD 5,950,000 by subscribing for CAD 7,300,000 aggregate principal amount of convertible debentures, inclusive of the commitment fee, in twenty tranches, each in the aggregate principal amount of CAD 350,000 each tranche convertible upon notice at the lower of the closing price of the common shares on the CSE at the time of delivery of the relevant conversion notice to the corporation and CAD 0.05; the convertible debentures shall be subscribed for at a subscription price of eighty-five percent of the par value of the convertible debentures. 41,650,000 warrants exercisable at CAD 0.05 shall be attached to the first tranche. In connection with the subscription agreement, the company has agreed to pay the subscriber a commitment fee of CAD 300,000 where CAD 150,000 shall be added to the principal amount of the debentures issued in connection with each of the first two tranches.
お知らせ • Feb 04Silo Wellness Inc. announced that it expects to receive $0.494988 million in funding from Orthogonal Thinker, Inc., Investment ArmSilo Wellness Inc. announced that it has entered into an subscription agreement to issue 12,555,180 units at a price of $0.039425 per unit for gross proceeds of up to $494,988 on February 3, 2022. The transaction will include participation from new investor Orthogonal Thinker, Inc., Investment Arm. Each unit will consist of one common share and one common share purchase warrant. Each warrant will be exercisable at CAD 0.05 per share for two years following the closing date of the offering. The offering is subject to customary closing conditions, applicable regulatory approvals, including receipt of certain voting support agreements from certain shareholders of the company. David Nikzad and Jason Hobson from Orthogonal Thinker, Inc., Investment Arm will join company's board of director.
お知らせ • Jun 25Silo Wellness Inc. Debuts Marley One, the First Global Functional and Psychedelic Mushroom Brand, in Collaboration with the Bob Marley FamilySilo Wellness Inc. announced the launch of Marley One, the first global functional and psychedelic mushroom consumer brand, in collaboration with the family of Bob Marley. The initial product offering will include a range of functional mushroom tinctures with unique blends highlighting the brand’s connection to Jamaica, including species such as cordyceps, lion's mane, chaga, reishi and turkey tail that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. The Company intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics. In March, Silo Wellness announced a multi-year licensing agreement with the family of global reggae icon Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. At launch, the Marley One product line includes: One Mind: A coffee-flavored blend of lion’s mane and L-theanine designed to improve focus and cognitive function. One Flow: A peppermint-flavored blend of cordyceps and ginseng designed to enhance physical endurance and mental function. One Harmony: A mango-flavored blend of chaga and ginger designed to stimulate gut health and improve digestion. One Body: A berry-flavored blend of turkey tail and astragalus designed to support immune health. One Rest: A vanilla-flavored blend of reishi and GABA designed to help reduce tension and stress and improve quality of sleep.
